Evaluation des bénéfices marchands et non-marchands du végétal en ville

Evaluation des bénéfices marchands et non-marchands du végétal en vill

Evaluation des bénéfices marchands et non-marchands du végétal en ville

Evaluation des bénéfices marchands et non-marchands du végétal en vill

Evaluation des bénéfices marchands et non-marchands du végétal en ville

Evaluation des bénéfices marchands et non-marchands du végétal en vill

Florelocale : Un signe national pour encadrer la production d’espèces végétales sauvages d’origine locale. I

National audienc

Florelocale : Un signe national pour encadrer la production d’espèces végétales sauvages d’origine locale. I

National audienc

Nature sauvage pour une nouvelle qualité de vie : perception citadine de la flore spontanée dans les espaces publics

International audienceno abstrac

Inventaire et évaluation des méthodes de lutte contre la processionnaire du pin. Enquête nationale-guide technique

National audienc

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations